Lots of ground work done.18 Jul 2024 23:42
Aminoindanes are a class of molecules that offer an alternative source of medical empathogens to MDMA for use alongside psycho-social support in the treatment of trauma related mental health disorders.
Aminoindanes have similar pharmacological properties to MDMA, they promote serotonin dopamine and noradrenaline release and block their reuptake. This combination of effects is believed to underpin the empathogenic activity. They offer a novel patentable approach to the treatment of trauma-related disorders.
Awakn acquired six years of proprietary research data from Prof. David Nutt, this data described potentially fast acting aminoindane compounds
Awakn has completed a Hit to Lead (HtL) program with Evotec. In vitro and in vivo data shows efficacy for drug-like hits, defining chemical series for lead optimization. Awakn has filed patents for two promising chemical series identified for lead optimization